Application of 20(s)-protopanaxadiol in preparation of antidepressants

Abstract

The invention provides the novel use of 20(S)-protopanaxadiol in the preparation of medicaments for the treatment of depressive psychiatric disorders. The pharmacological test results indicated that the compound could remarkably increase the level of NE, 5-HT and HAV in the brains of model rats having depressive disorders, remarkably enhance tremors induced by 5-hydroxytryptophan (5-HTP) and behavioral effects induced by levodopa, and inhibit the re-uptake of 5-HT and NA.

1 - 20 . (canceled) 
     
     
         21 . A pharmaceutical composition comprising 20(S)-protopanaxadiol and a pharmaceutically acceptable additive. 
     
     
         22 . The pharmaceutical composition according to claim  1 , wherein the pharmaceutical composition is formulated in a form of an orally administrable solution, an injectable solution, a tablet, a capsule, a pill or granules. 
     
     
         23 . The pharmaceutical composition according to claim  1 , wherein the pharmaceutical acceptable additive is selected from the group consisting of solvent, emulsifier, sweetener, salt, adhesive, or a combination thereof. 
     
     
         24 . The pharmaceutical composition according to claim  3 , wherein the solvent is water, ethanol, or a combination thereof. 
     
     
         25 . The pharmaceutical composition according to claim  3 , wherein the emulsifier is Tween, Span, or a combination thereof. 
     
     
         26 . The pharmaceutical composition according to claim  3 , wherein the sweetener is sucrose, lactose, or a combination thereof. 
     
     
         27 . The pharmaceutical composition according to claim  3 , wherein the salt is magnesium stearate, CMCNa, sodium chloride, or a combination thereof. 
     
     
         28 . The pharmaceutical composition according to claim  1 , wherein the pharmaceutical composition comprises 20(S)-protopanaxadiol in a suspension of 0.3% sodium carboxymethyl cellulose (CMCNa)/Tween-80 solution. 
     
     
         29 . The pharmaceutical composition according to claim  1 , wherein the pharmaceutically acceptable additives are a combination of lactose, ethanol, water and magnesium stearate. 
     
     
         30 . The pharmaceutical composition according to claim  1 , wherein the pharmaceutical composition comprises 20(S)-protopanaxadiol in a suspension of 0.3% CMCNa/Tween-80 solution. 
     
     
         31 . The pharmaceutical composition according to claim  1 , wherein the pharmaceutically acceptable additives are a combination of lactose, ethanol, water and magnesium stearate.